Discovery of Novel Peptidomimetics for Brain-Derived Neurotrophic Factor using Phage Display Technology Designing a BDNF-mimicking peptide
Iranian Journal of Pharmaceutical Sciences,
Vol. 14 No. 4 (2018),
1 October 2018
,
Page 9-20
https://doi.org/10.22037/ijps.v14.40619
Abstract
Brain-Derived Neurotrophic Factor (BDNF) is a neuroprotectant candidate for neurodegenerative diseases. However, there are several clinical concerns about its therapeutic applications. In the current study, we selected BDNF-mimicking small peptides from phage-displayed peptide library as alternative molecules to the clinical challenges. The peptide library was screened against BDNF receptor (Neurotrophic Tyrosine Kinase Receptor Type 2, NTRK2) and evaluated by ELISA. Polyclonal phage ELISA indicated that target populations were enriched round by round and the panning process was truly effective. The results of monoclonal phage-ELISA showed that all clones had principally bound to NTRK2 but fifteen best clones were sequenced, which twelve of them have SGVYKVAYDWQH (peptide 1) sequence, two pairs were GLHTSATNLYLH (peptide 2), and TVLSHPSTATLI (peptide 3) and one sequence was QQRPYVQDLRLI (peptide 4). Alignment of these peptides and BDNF sequence showed that the resulting peptides conformationally mimicked loop 2 (E40-KVPVSKGQLK-Q51) of BDNF. This region of BDNF is responsible for specific receptor binding and biological activity. According to the similarity of these peptides with BDNF, they could be considered as novel peptidomimetics with therapeutic properties. In addition, modeled peptides were submitted to Protein Model Data Base (peptides 1, 2, 3 and 4 as PMDB ID: PM0081104, PM0081105, PM0081106, PM0081107, respectively).
- Brain-Derived Neurotrophic Factor
- Neurotrophic Tyrosine Kinase Receptor Type 2
- phage display peptide library
- peptidomimetic
- agonist
- neuroprotectant
How to Cite
References
[2] Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat. Rev. Drug Discov. (2011)10(3):209-219.
[3] Costa A, Peppe A, Carlesimo GA, Zabberoni S, Scalici F, Caltagirone C, Angelucci F. Brain-derived neurotrophic factor serum levels correlate with cognitive performance in Parkinson’s disease patients with mild cognitive impairment. Front. Behav. Neurosci. (2015)9(1):1-8.
[4] Ventriglia M, et al. Serum brain-derived neurotrophic factor levels in different neurological diseases. BIOMED. RES. INT. (2013)2013(1):1-7.
[5] Budni J, Bellettini-Santos T, Mina F, Garcez ML, Zugno AI. The involvement of BDNF, NGF and GDNF in aging and Alzheimer’s disease. Aging Dis. (2015)6(5):331-341.
[6] Ihara K, et al. Serum BDNF levels before and after the development of mood disorders: a case–control study in a population cohort. Transl. Psychiatry (2016)6(4):782-789.
[7] Ma X-c, et al. Intranasal Delivery of Recombinant AAV Containing BDNF Fused with HA2TAT: a Potential Promising Therapy Strategy for Major Depressive Disorder. Sci. Rep. (2016)6(22):404-413.
[8] Fyfe I. Movement disorders: Targeted RNA or BDNF gene transfer protects against frataxin deficiency. Nature Reviews Neurology. (2016)19.
[9] Nagahara AH, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat. Med. (2009)15(3):331-337.
[10] Tuszynski MH, Nagahara AH. NGF and BDNF Gene Therapy for Alzheimer’s Disease. Transl. Neurosci. (2016)2016(1):33-64.
[11] White AO, et al. BDNF rescues BAF53b-dependent synaptic plasticity and cocaine-associated memory in the nucleus accumbens. Nat. Commun.. (2016)7(117):25-37.
[12] Matsuoka Y, et al. Serum pro-BDNF/BDNF as a treatment biomarker for response to docosahexaenoic acid in traumatized people vulnerable to developing psychological distress: a randomized controlled trial. Transl. Psychiatry. (2015)5(7):596-602.
[13] Xue W, et al. PKA-CREB-BDNF signaling regulated long lasting antidepressant activities of Yueju but not ketamine. Sci Rep. (2016)6:26331.
[14] Kozisek ME, Middlemas D, Bylund DB. Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies. Pharmacol Ther. (2008)117(1):30-51.
[15] Song J-H, Yu J-T, Tan L. Brain-derived neurotrophic factor in Alzheimer’s disease: risk, mechanisms, and therapy. Mol. Neurobiol. (2015)52(14):77-93.
[16] Novkovic T, Mittmann T, Manahan‐Vaughan D. BDNF contributes to the facilitation of hippocampal synaptic plasticity and learning enabled by environmental enrichment. Hippocampus (2015)25(1):1-15.
[17] O'Leary PD, Hughes RA. Design of potent peptide mimetics of brain-derived neurotrophic factor. J. Biol. Chem. (2003)278(257):38-44.
[18] Massa SM, et al. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J. Clin. Invest. (2010)120(17):74-85.
[19] Longo FM, Xie Y, Massa SM. Neurotrophin small molecule mimetics: candidate therapeutic agents for neurological disorders. Cent. Nerv. Syst. Agents Med. Chem. (2005)5(1):29-41.
[20] Katsu-Jiménez Y, Loría F, Corona JC, Díaz-Nido J. Gene Transfer of Brain-derived Neurotrophic Factor (BDNF) Prevents Neurodegeneration Triggered by FXN Deficiency. Mol. Ther. (2016)24(5):877-889.
[21] Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: molecular evolutionary genetics analysis version 6.0. Mol. Biol. Evol. (2013)30(12):2725-2729.
[22] Lamiable A, Thévenet P, Rey J, Vavrusa M, Derreumaux P, Tufféry P. PEP-FOLD3: faster de novo structure prediction for linear peptides in solution and in complex. Nucleic Acids Res. (2016)2016(1):449-454.
[23] Maupetit J, Derreumaux P, Tufféry P. A fast method for large scale De Novo peptide and miniprotein structure prediction. J. Comput. Chem.(2010)31(4):726-738.
[24] Frith MC, Saunders NF, Kobe B, Bailey TL. Discovering sequence motifs with arbitrary insertions and deletions. PLoS Comput Biol. (2008)4(4):1-12.
[25] Guharoy M, Chakrabarti P. Secondary structure based analysis and classification of biological interfaces: identification of binding motifs in protein–protein interactions. Bioinformatics. (2007)23(15):1909-1918.
[26] Tyndall JD, Nall T, Fairlie DP. Proteases universally recognize beta strands in their active sites. Chem. Rev. (2005)105(3):973-1000.
[27] Ibanez C, Ebendal T, Persson H. Chimeric molecules with multiple neurotrophic activities reveal structural elements determining the specificities of NGF and BDNF. The EMBO journal. (1991)10(8):2105-2110.
[28] Ibanez C, Ilag L, Murray-Rust J, Persson H. An extended surface of binding to Trk tyrosine kinase receptors in NGF and BDNF allows the engineering of a multifunctional pan-neurotrophin. EMBO J. (1993)12(6):2281.
[29] Ilag LL, Lönnerberg P, Persson H, Ibáñez CF. Role of variable beta-hairpin loop in determining biological specificities in neurotrophin family. J. Biol. Chem. (1994)269(31):19941-19946.
[30] O'Leary P, Hughes R. Structure‐Activity Relationships of Conformationally Constrained Peptide Analogues of Loop 2 of Brain‐Derived Neurotrophic Factor. J. Neurochem. (1998)70(4):1712-1721.
[31] Fletcher JM, Hughes RA. Novel monocyclic and bicyclic loop mimetics of brain derived neurotrophic factor. J. Pept. Sci. (2006)12(8):515-524.
[32] Nafian F, Rasaee M, Yazdani S, Daftarian N, Soheili Z, Kamali Doust Azad B. Peptide selected by phage display increases survival of SH-SY5Y neurons comparable to brain-derived neurotrophic factor. J. Cell Biochem. 2018;120(3):1‐11.
- Abstract Viewed: 78 times
- IJPS_Volume 14_Issue 4_Pages 9-20 Downloaded: 19 times